The alternate effects of anti-TNFα therapeutics and their role in mycobacterial granulomatous infection in Crohn’s disease

References

• Loftus EV. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–1517.
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3(7):390–407.
   PubMedGoogle Scholar
• Qasem A, Abdel-Aty A, Abu-Suwa H, et al. Oxidative stress due to Mycobacterium avium subspecies paratuberculosis (MAP) infection upregulates selenium-dependent GPx activity. Gut Pathog. 2016;8(1):12.
   PubMed Web of Science ®Google Scholar
• Naser SA, Schwartz D, Shafran I. Isolation of Mycobacterium avium subsp paratuberculosis from breast milk of Crohn’s disease patients. Am J Gastroenterol. 2000;95(4):1094.
   PubMed Web of Science ®Google Scholar
• Naser SA, Ghobrial G, Romero C, et al. Culture of Mycobacterium avium subspecies paratuberculosis from the blood of patients with Crohn’s disease. The Lancet. 2004;364(9439):1039–1044.
   PubMed Web of Science ®Google Scholar
• Antoni C, Braun J. Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol. 2002;20(6; SUPP/28):S–152.
   PubMed Web of Science ®Google Scholar
• Furst DE, Wallis R, Broder M, et al. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006 December;36(3):159–167. WB Saunders.
   PubMed Web of Science ®Google Scholar
• Murch SH, Lamkin VA, Savage MO, et al. Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut. 1991;32(8):913–917.
   PubMed Web of Science ®Google Scholar
• Braegger CP, Nicholls S, Murch SH, et al. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. The Lancet. 1992;339(8785):89–91.
   PubMed Web of Science ®Google Scholar
• Roach DR, Bean AG, Demangel C, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunology. 2002;168(9):4620–4627.
   PubMed Web of Science ®Google Scholar
• Mpofu S, Fatima F, Moots RJ. Anti-TNF-α therapies: they are all the same (aren’t they?). Rheumatology. 2005;44(3):271–273.
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity. 1995;2(6):561–572.
   PubMed Web of Science ®Google Scholar
• Turner J, Frank AA, Brooks JV, et al. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology. 2001;102(2):248–253.
   PubMed Web of Science ®Google Scholar
• Denis M. Tumor necrosis factor and granulocyte macrophage-colony stimulating factor stimulate human macrophages to restrict growth of virulent Mycobacterium avium and to kill avirulent M. avium: killing effector mechanism depends on the generation of reactive nitrogen intermediates. J Leukoc Biol. 1991;49(4):380–387.
   PubMed Web of Science ®Google Scholar
• Greil J, Bodendorfer B, RÖLlinghoff M, et al. Application of recombinant granulocyte‐macrophage colony‐stimulating factor has a detrimental effect in experimental murine leishmaniasis. Eur J Immunol. 1988;18(10):1527–1534.
   PubMed Web of Science ®Google Scholar
• Denis M, Gregg EO, Ghandirian E. Cytokine modulation of Mycobacterium tuberculosis growth in human macrophages. Int J Immunopharmacol. 1990;12(7):721–727.
   PubMed Web of Science ®Google Scholar
• Jouanguy E, Altare F, Lamhamedi S, et al. Interferon-γ–receptor deficiency in an infant with fatal bacille Calmette–Guérin infection. New England J Med. 1996;335(26):1956–1962.
   PubMed Web of Science ®Google Scholar
• Wallis RS, Saliu OY, Sofer C, et al. (2005). Effect of TNF blockers on expression of mycobacterial immunity in vitro. In International Conference on the Pathogenesis of Mycobacterial Infections (p. 6).
   Google Scholar
• Shin SJ, Collins MT. Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro. Antimicrob Agents Chemother. 2008;52(2):418–426.
   PubMed Web of Science ®Google Scholar
• Greenstein RJ, Su L, Juste RA, et al. On the action of cyclosporine A, rapamycin and tacrolimus on M. avium including subspecies paratuberculosis. Plos One. 2008;3(6):e2496.
   PubMed Web of Science ®Google Scholar
• Greenstein RJ, Su L, Haroutunian V, et al. On the action of methotrexate and 6-mercaptopurine on M. avium subspecies paratuberculosis. Plos One. 2007;2(1):e161.
   PubMed Web of Science ®Google Scholar
• Pizzorno GDRB, Handschumacher R, Cheng YC. Pyrimidine and purine antimetabolites. In: Bast RC, Kufe DW, Pollock RE, et al., eds. Cancer medicine. Ontario, Canada: BC Decker Inc; 2000. p. 625–647.
   Google Scholar
• Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. New England J Med. 1995;332(5):292–297.
   PubMed Web of Science ®Google Scholar
• Alcedo KP, Thanigachalam S, Naser SA. RHB-104 triple antibiotics combination in culture is bactericidal and should be effective for treatment of Crohn’s disease associated with Mycobacterium paratuberculosis. Gut Pathogens. 2016;8(1):32.
   PubMed Web of Science ®Google Scholar
• Qasem A, Safavikhasraghi M, Naser SA. A single capsule formulation of RHB-104 demonstrates higher anti-microbial growth potency for effective treatment of Crohn’s disease associated with Mycobacterium avium subspecies paratuberculosis. Gut Pathogens. 2016;8(1):45.
   PubMed Web of Science ®Google Scholar
• Borody TJ, Leis S, Warren EF, et al. Treatment of severe Crohn’s disease using antimycobacterial triple therapy – approaching a cure? Dig Liver Dis. 2002;34(1):29–38.
   PubMedGoogle Scholar
• Selby W, Pavli P, Crotty B, et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology. 2007;132(7):2313–2319.
   PubMed Web of Science ®Google Scholar
• Chamberlin W, Ghobrial G, Chehtane M, et al. Successful treatment of a Crohn’s disease patient infected with bacteremic Mycobacterium paratuberculosis. Am J Gastroenterol. 2007;102(3):689.
   PubMed Web of Science ®Google Scholar
• Bach H, Sun J, Hmama Z, et al. Mycobacterium avium subsp. paratuberculosis PtpA is an endogenous tyrosine phosphatase secreted during infection. Infect Immun. 2006;74(12):6540–6546.
   PubMed Web of Science ®Google Scholar
• Wong D, Bach H, Sun J, et al. Mycobacterium tuberculosis protein tyrosine phosphatase (PtpA) excludes host vacuolar-H+–ATPase to inhibit phagosome acidification. Proc Natl Acad Sci. 2011;108(48):19371–19376.
   PubMed Web of Science ®Google Scholar
• Bach H, Papavinasasundaram KG, Wong D, et al. Mycobacterium tuberculosis virulence is mediated by PtpA dephosphorylation of human vacuolar protein sorting 33B. Cell Host Microbe. 2008;3(5):316–322.
   Web of Science ®Google Scholar
• Bach H, Ko HH, Raizman EA, et al. Immunogenicity of Mycobacterium avium subsp. paratuberculosis proteins in Crohn’s disease patients. Scand J Gastroenterol. 2011;46(1):30–39.
   PubMed Web of Science ®Google Scholar
• Bach H, Rosenfeld G, Bressler B. Treatment of Crohn’s disease patients with infliximab is detrimental for the survival of Mycobacterium avium ssp. paratuberculosis within macrophages and shows a remarkable decrease in the immunogenicity of mycobacterial proteins. Journal of Crohn’s and Colitis. 2012;6(5):628–629.
   PubMed Web of Science ®Google Scholar
• Xia A, Stempak JM, Grist J, et al. Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins. Scand J Gastroenterol. 2014;49(2):157–163.
   PubMed Web of Science ®Google Scholar
• Etanercept [package insert]. Thousand Oaks, CA: Amgen Inc; 2015.
   Google Scholar
• Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38(9):1261–1265.
   PubMed Web of Science ®Google Scholar
• Ruderman EM, Markenson JA. Granulomatous infections and tumor necrosis factor antagonist therapies. In Annals of the Rheumatic Diseases. England: BMJ Publishing Group. 2003;62:172-173.
   Web of Science ®Google Scholar
• Gómez‐Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active‐surveillance report. Arthritis Rheum. 2003;48(8):2122–2127.
   PubMed Web of Science ®Google Scholar
• Perez JL, Kupper H, Spencer-Green GT. Impact of screening for latent TB prior to initiating anti-TNF therapy in North America and Europe. In Annals of the Rheumatic Diseases. England: BMJ Publishing Group. 2005;64:86-86.
   Google Scholar
• Lee JH, Slifman NR, Gershon SK, et al. Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept. Arthritis Rheum. 2002;46(10):2565–2570.
   PubMed Web of Science ®Google Scholar
• Slifman NR, Gershon SK, Lee JH, et al. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor α–neutralizing agents. Arthritis Rheum. 2003;48(2):319–324.
   PubMed Web of Science ®Google Scholar
• Van Deventer SJH, D’haens G, Van Deventer S, et al. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med. 2001;2001(344):1099–1100.
   Google Scholar
• Grattendick KJ, Nakashima JM, Feng L, et al. Effects of three anti-TNF-α drugs: etanercept, infliximab and pirfenidone on release of TNF-α in medium and TNF-α associated with the cell in vitro. Int Immunopharmacol. 2008;8(5):679–687.
   PubMed Web of Science ®Google Scholar
• Mohler KM, Torrance DS, Smith CA, et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol. 1993;151(3):1548–1561.
   PubMed Web of Science ®Google Scholar
• Oku H, Nakazato H, Horikawa T, et al. Pirfenidone suppresses tumor necrosis factor-α, enhances interleukin-10 and protects mice from endotoxic shock. Eur J Pharmacol. 2002;446(1):167–176.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Sarzi-Puttini P. Autoantibody production in patients treated with anti-TNF-α. Expert Rev Clin Immunol. 2008;4(2):275–280.
   PubMed Web of Science ®Google Scholar
• Caprioli F, Pallone F, Monteleone G. Cytokine therapies in Crohn’s disease: where are we now and where should we go? Inflamm Allergy Drug Targets. 2011;10(1):47–53.
   PubMedGoogle Scholar
• Atzeni F, Benucci M, Sallì S, et al. Different effects of biological drugs in rheumatoid arthritis. Autoimmunity Reviews. 2013;12(5):575–579.
   PubMed Web of Science ®Google Scholar
• Bendtzen K, Ainsworth M, Steenholdt C, et al. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44(7):774–781.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Guerra I, Muñoz‐Linares P, et al. Systematic review: antibodies and anti‐TNF‐α levels in inflammatory bowel disease. Aliment Pharmacol Ther. 2012;35(9):971–986.
   PubMed Web of Science ®Google Scholar
• Charles PJ, Smeenk RJT, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthritis Rheum. 2000;43(11):2383–2390.
   PubMed Web of Science ®Google Scholar
• Atzeni F, Talotta R, Salaffi F, et al. Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmunity Reviews. 2013;12(7):703–708.
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor α–neutralizing agent. New England J Med. 2001;345(15):1098–1104.
   PubMed Web of Science ®Google Scholar
• Keane J, Gershon SK, Braun MM. Tuberculosis and treatment with infliximab. N Engl J Med. 2002;346(625):6.
   Google Scholar
• Marotte H, Charrin JE, Miossec P. Infliximab-induced aseptic meningitis. The Lancet. 2001;358(9295):1784.
   PubMed Web of Science ®Google Scholar
• Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clinic Proceedings. 2001 June;76(6):653–656. Elsevier.
   PubMed Web of Science ®Google Scholar
• Ritz MA, Jost R. Severe pneumococcal pneumonia following treatment with infliximab for Crohn’s disease. Inflamm Bowel Dis. 2001;7(4):327–327.
   PubMed Web of Science ®Google Scholar
• Mozaffari S, Nikfar S, Abdolghaffari AH, et al. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14(5):583–600.
   PubMed Web of Science ®Google Scholar
• Roda G, Jharap B, Neeraj N, et al. Loss of response to anti-TNFs: definition, epidemiology, and management. Clin Transl Gastroenterol. 2016;7(1):e135.
   PubMed Web of Science ®Google Scholar
• Coskun M, Vermeire S, Nielsen OH. Novel targeted therapies for inflammatory bowel disease. Trends Pharmacol Sci. 2017;38(2):127-142.
   PubMed Web of Science ®Google Scholar
• Nitzan O, Elias M, Peretz A, et al. Role of antibiotics for treatment of inflammatory bowel disease. World J Gastroenterol. 2016;22(3):1078.
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Rezaie A, et al. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther. 2006;28(12):1983–1988.
   PubMed Web of Science ®Google Scholar